Biotricity Inc., a medical technology company specializing in biometric data monitoring solutions, reported its financial results for the three months ended March 31, 2025. The company achieved a positive Adjusted EBITDA of $438,260, a significant improvement compared to a negative $2.56 million for the same period in the previous fiscal year. This change reflects the company's ongoing efforts to enhance operational efficiency. The net loss attributable to common stockholders for the three months ended March 31, 2025, was approximately $2.02 million, compared to a net loss of $4.4 million in the corresponding period of the prior year. This reduction in net loss indicates a positive trend in the company's financial performance. Biotricity continues to focus on delivering innovative, remote monitoring solutions for the medical, healthcare, and consumer markets, emphasizing diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. The company is committed to applying innovation within existing business models where reimbursement is established, aiming to reduce risk in its operations.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biotricity Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-019755), on July 15, 2025, and is solely responsible for the information contained therein.
Comments